DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/8g3pmw/asthma_event) has announced the addition of Decision Resources, Inc's new report "Asthma (Event Driven)" to their offering.
With a large and growing patient population, the asthma market is one of the most lucrative drug markets in the pharmaceutical industry. However, generic and/or branded-generic price erosion, increased product competition, and a difficult reimbursement environment will stabilize the asthma market over the forecast period despite opportunities for growth.
The uptake of the first once-daily, long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations and novel anticytokine therapies within the next ten years will fuel growth of the market. Despite a high level of satisfaction with current therapies, opportunity still exists for the development of new agents that target the heterogeneous population of patients with severe, corticosteroid-refractory asthma. An emerging therapy that serves even a niche of this underserved segment of the asthma market will have considerable sales potential.
Key Topics Covered:
What are the key parameters of the asthma market?
What factors are driving the market for asthma therapies?
What factors are constraining the market for asthma therapies?
What are the drug development activities of note in asthma?
What do the experts say?
What key challenges and opportunities remain?
1 Etiology and Pathophysiology
2 Epidemiology and Patient Populations
3 Current Therapies and Medical Practice
4 Unmet Needs
5 Emerging Therapies
6 Market Outlook
Tables and Figures
For more information visit http://www.researchandmarkets.com/research/8g3pmw/asthma_event
Source: Decision Resources, Inc
Source: Research and Markets